Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating accelerated transformation toward innovation and globalization. Total operating revenue reached RMB 41.662 billion (+1.45% YoY), with innovative drug revenue surging 29.59% to RMB 9.893 billion – now 33.16% of pharmaceutical sales. Overseas revenue grew 14.87% to RMB 12.977 billion (31.15% of total), while net profit attributable to shareholders jumped 21.69% to RMB 3.371 billion.
Financial Highlights
Metric
2025 Result
YoY Change
Strategic Significance
Total Operating Revenue
RMB 41.662 billion
+1.45%
Stable base amid portfolio optimization
Innovative Drug Revenue
RMB 9.893 billion
+29.59%
Core growth engine – 33.16% of pharma sales
Overseas Revenue
RMB 12.977 billion
+14.87%
31.15% of total (+3.64pp) – globalization accelerating
Net Profit (Parent)
RMB 3.371 billion
+21.69%
Margin expansion from high-value innovation
Recurring Net Profit
RMB 2.34 billion
+1.12%
Sustainable earnings quality
Operating Cash Flow
RMB 5.213 billion
+16.45%
Strong cash generation supports R&D intensity
R&D Investment & Pipeline Productivity
R&D Metric
2025 Result
YoY Change
Innovation Focus
Total R&D Investment
RMB 5.913 billion
+6.46%
Sustained high-intensity investment
Innovative Pharma R&D
RMB 4.303 billion
+15.98%
80.26% of pharma R&D – prioritization clear
New Approvals (Indications)
16 indications of 7 drugs
—
China + overseas regulatory success
NDAs Accepted
6 candidates
—
Near-term commercialization pipeline
Clinical Trial Approvals
~40 trials (China + global)
—
Robust late-stage engine
NRDL Inclusions (2025)
5 innovative drugs
—
Reimbursement access unlocking volume
Commercial Insurance Listing
Yikaida (CAR-T) in 1st Catalog
—
Alternative payment pathway for cell therapy
Therapeutic Area Progress
Segment
2025 Milestones
Strategic Impact
Oncology
Fumaining® (luvometinib) 2 approvals – rare tumor gap filled; Futuoning® (CDK4/6) launched for breast cancer; Serplulimab EU approval for ES-SCLC – first China PD-1 in EU; HLX43/HLX22 ADCs enter key phases; Brexucabtagene Autoleucel NDA accepted
Global oncology franchise established with biosimilars, PD-1, ADCs, CAR-T
Opicapone (Parkinson’s) Boao launch; MRgFUS upgrade; Sodium Oligomannate post-marketing trials; AR1001 Phase III global
Long-term CNS pipeline for aging populations
Technology Platforms & Global Licensing
Platform
2025 Progress
Deal Value
Radiopharmaceuticals
SRT-007 Phase I initiated – “imaging + therapy” pathway
—
Cell Therapy
FKC289 (dual-target CAR-T) NMPA IND accepted
—
GLP-1 (YP05002)
Global out-license – largest deal of 2025
$150M upfront + $2.085B total
Total Out-Licensing
$260M+ upfront across all deals
$3.8B+ potential milestones
Global Partnerships: Teva joint development (FXB0871); Aditum Bio fund collaboration; Akynzeo, Pu Rui Ni, Daxxify China in-licensing approvals
Globalization: “System-Centric” Upgrade
Capability
2025 Achievement
Geographic Reach
Serplulimab
Approved 40+ countries; U.S. bridging study enrolled; BLA submission 2026
China, EU, emerging markets, U.S. (pending)
Biosimilars
Denosumab FDA + EU approvals – biologics platform certified to international standards
Global supply to Europe, LatAm, SE Asia, India
GMP Certifications
17 workshops/lines passed U.S., EU, WHO GMP
Quality foundation for global supply
Manufacturing Scale
Biologics regular global supply; Gland Pharma injections EU/U.S./Japan/Australia certified
Supply chain resilience across 6+ regions
Commercial Presence
6,000+ personnel worldwide; Africa 40+ countries; Sisram 110+ countries; Breas 50+ countries
“Independent operation + licensing” dual model
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026 BLA submissions, NRDL negotiations, and global expansion execution. Actual results may differ due to regulatory review timelines, competitive dynamics in oncology and metabolic diseases, and geopolitical factors affecting China-origin pharmaceutical exports.-Fineline Info & Tech
By Fineline Cube 